SynVivo
SynVivo Inc. develops organ-on-a-chip and microfluidic cell-based assay platforms, including five specialized organ models (BBB, tumor, lung, inflammation, toxicology) and supporting instruments, selling to pharmaceutical companies and academic researchers via direct e-commerce and a global distributor network.
- Company typePrivate
- Founded2014
- HeadquartersHuntsville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SynVivo does
SynVivo Inc. is a privately-held US company headquartered in Huntsville, Alabama, that develops and sells organ-on-a-chip and microfluidic cell-based assay platforms for drug discovery, toxicology, and translational research. Its core technology centers on synthetic microvascular network (SMN) chips that replicate in vivo microvasculature with dynamic flow and shear stress conditions, supporting five specialized organ models: SynBBB (blood-brain barrier), SynTumor (cancer-on-a-chip), SynALI (lung/air-liquid interface), SynRAM (inflammation/leukocyte-endothelium), and SynTox (toxicology), plus a newer multiorgan brain-lung platform. Supporting instruments include pneumatic primers, cell impedance analyzers, syringe pumps, and stage top incubators, alongside microfluidic chips (linear, bifurcating, idealized networks), accessories, custom assay development services, and workshops.
The company sells through a direct e-commerce storefront (synvivobio.com) complemented by a global distributor network, targeting pharmaceutical and biotechnology companies as well as academic and research institutions. Pricing is quote-based across all products and services, with terms of 30 days from invoice date and FOB facility shipping. Products are explicitly labeled for research use only, not for human or animal therapeutic or diagnostic use. SynVivo has built scientific credibility through over 50 peer-reviewed publications in journals including PNAS, Journal of Controlled Release, and Analytical Chemistry, and was recognized as a Top 10 Innovation of 2013 by The Scientist magazine. The company operates with fewer than 10 employees, has no disclosed funding rounds or investors, and is governed under Delaware law.
Leadership consists of Gwen Fewell, PhD as President and CEO; Balabhaskar Prabhakarpandian, PhD as CTO; Deborah Ramsey, PhD as Director of Scientific Development; and Shreyas Galkwad, PhD as Research Scientist. The company's positioning aligns with regulatory tailwinds from the FDA Modernization Act and New Approach Methodologies (NAMs), and from European animal testing restrictions, positioning its human-relevant in vitro models as alternatives to traditional animal-based preclinical testing.
SynVivo firmographics
Firmographics- Name
- SynVivo
- Legal name
- SynVivo Inc.
- Website
- https://synvivobio.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SynVivo Inc. develops organ-on-a-chip and microfluidic cell-based assay platforms, including five specialized organ models (BBB, tumor, lung, inflammation, toxicology) and supporting instruments, selling to pharmaceutical companies and academic researchers via direct e-commerce and a global distributor network.
- Ownership category
- akta.pro rank
SynVivo industry classification
Industry- Product category
- Organ-on-Chip Technology Platforms
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where SynVivo is headquartered
LocationHeadquarters
- HQ city
- Huntsville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SynVivo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- 3D Tissue and Organ-on-Chip Products: Sale of ready-to-use organ-on-chip models including SynBBB, SynTumor, SynALI, SynRAM, and SynTox for drug discovery and research applications.
- Microfluidic Chips and Instruments: Sale of microfluidic chips (linear channels, bifurcating channels, microvascular networks) and supporting instruments (pneumatic primer, cell impedance analyzer, syringe pumps, stage top incubators).
- Screening and Assay Development Services: Custom assay development and screening services for specific research requirements using SynVivo platforms.
- Workshops and Training: Educational workshops and training programs on organ-on-chip technologies and applications.
- Accessories: Sale of supporting accessories for microfluidic experiments and cell culture.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for all products and services |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
SynVivo product offering
Product offeringCore offering
SynVivo develops and sells cell-based microfluidic organ-on-a-chip platforms that replicate native tissue microenvironments with dynamic flow and shear stress conditions for drug discovery, toxicology, and translational research. The product portfolio includes ready-to-use 3D organ models (SynBBB, SynTumor, SynALI, SynRAM, SynTox), microfluidic chips, supporting instruments, and accessories, complemented by custom screening/assay development services and training workshops for the pharma, biotech, and academic research communities.
Differentiator
Problem solved
Functional benefit
Products and services
- SynBBB 3D Blood Brain Barrier Model
- SynRAM 3D Inflammation Model Inflammation-on-a-chip platform for immunology and inflammation researchers studying leukocyte-endothelium interactions, rolling adhesion, and migration under physiological flow.
- SynTumor 3D Cancer Model Cancer-on-a-chip platform for oncology researchers visualizing 3D tumor cluster growth, tumor perfusion via vascular network, and real-time drug delivery monitoring.
- SynALI Lung Model Small airway lung-on-a-chip model for respiratory researchers supporting air-liquid interface culture with ciliated cells and mucus production for studying respiratory infection and barrier function.
- SynTox 3D Toxicology Model 3D toxicology platform for safety assessment researchers featuring a complete vascular lumen under flow for studying systemic toxicology and immunotoxicology responses.
- Microfluidic Chips Standalone microfluidic chip products including linear channels, bifurcating channels, microvascular networks, and idealized networks for researchers building custom cell-based assays.
- Instruments Supporting laboratory instruments for organ-on-chip workflows, including pneumatic primer, cell impedance analyzer, syringe pumps, and stage top incubators for researchers operating the SynVivo platforms.
- Accessories Supporting accessories for microfluidic experiments and cell culture, sold as consumables and complementary items for SynVivo platform users.
- Screening & Assay Development Services Custom assay development and screening services for pharmaceutical, biotechnology, and academic research teams with specific experimental requirements using the SynVivo platforms.
- Workshops & Trainings Educational workshops and training programs on organ-on-chip technologies and applications, targeted at researchers and laboratory teams adopting SynVivo platforms.
Quantifiable outcome
- Cells cultured in SynVivo chips retain physiological function and gene expression patterns comparable to in vivo
- +1 more outcomes
Companies that use SynVivo
Customer profileSegments3 records
Ideal customer profiles2 records
SynVivo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
SynVivo partnerships and signals
Strategic signalScale indicators1 record
Expansion highlights5 records
SynVivo competitors and assessment
Company assessmentDirect peers
- TissUse: TissUse develops multi-organ chip systems (Humimic) for systemic substance testing, a directly comparable approach to SynVivo's multiorgan brain-lung platform in the preclinical toxicology and ADME use case.
- Emulate: Emulate is a venture-backed organ-on-chip company offering the Liver-Chip, Intestine-Chip, Lung-Chip, and Brain-Chip. It is the most directly comparable competitor to SynVivo in target customer (pharma/biotech), product category (microfluidic organ-on-chip), and use case (preclinical drug safety and efficacy).
- Nortis: Nortis produces organ-on-chip microfluidic platforms (chips, instruments, and services) for kidney, vascular, and toxicology applications—closely aligned with SynVivo's microfluidic chips and instruments portfolio and customer base.
- CN Bio: CN Bio provides organ-on-chip systems including the PhysioMimix platform for liver, lung, and multi-organ applications targeting pharmaceutical toxicology and disease modeling—directly overlapping with SynVivo's SynTumor, SynALI, SynTox, and multiorgan offerings.
- Mimetas: Mimetas offers the OrganoPlate, a microfluidic 3D cell culture platform for organ-on-chip applications including kidney, intestine, and tumor models, competing directly with SynVivo in the pharma/biotech drug discovery segment.
Emerging players
- InSphero: InSphero provides 3D cell-based assay platforms including microtissue models for liver, pancreas, and tumor applications. Adjacent to SynVivo's organ-on-chip focus, with overlap in drug discovery and toxicology end markets but a different underlying technology (spheroid vs. microfluidic).
- Kirkstall: Kirkstall manufactures the Quasi Vivo interconnected cell culture system for organ-on-chip and multi-organ applications, serving the same pharma/biotech research customer base as SynVivo.
- React4Life: React4Life develops organ-on-chip and 3D cell culture technologies including the MIVO platform for multi-organ fluidic modeling, directly overlapping with SynVivo's multiorgan fluidic interconnection capabilities.
Others
- Organovo: Organovo develops 3D bioprinted human tissues for preclinical research. While adjacent to SynVivo's organ-on-chip mission, its bioprinting-based approach is technologically distinct, making it more of a thematic peer than a direct competitor.
Broad incumbents
- Thermo Fisher Scientific: Thermo Fisher is a broad life sciences tools incumbent that sells competing cell culture instruments, consumables, and increasingly organ-on-chip-adjacent products. Its massive scale and catalog purchasing motion pose a long-term competitive threat to small specialty vendors like SynVivo.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
SynVivo social profiles
Digital presenceSynVivo financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynVivo leadership team
Management profileNumber of profiles
Profiles4 records
SynVivo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynVivo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynVivo
What does SynVivo do?
SynVivo develops and sells cell-based microfluidic organ-on-a-chip platforms that replicate native tissue microenvironments with dynamic flow and shear stress conditions for drug discovery, toxicology, and translational research. The product portfolio includes ready-to-use 3D organ models (SynBBB, SynTumor, SynALI, SynRAM, SynTox), microfluidic chips, supporting instruments, and accessories, complemented by custom screening/assay development services and training workshops for the pharma, biotech, and academic research communities.
Is SynVivo a public or private company?
SynVivo is a private company. It is classified as unknown and is currently operating.
When was SynVivo founded?
SynVivo was founded in 2014. It employs 1 to 10 people.
Where is SynVivo based?
SynVivo is headquartered in Huntsville, United States, in the North America region.
How does SynVivo make money?
Five revenue lines are on record. 3D Tissue and Organ-on-Chip Products are the primary driver. The others are microfluidic Chips and Instruments, screening and Assay Development Services, workshops and Training and accessories.
Who are SynVivo's main competitors?
Direct peers on record are TissUse, Emulate, Nortis, CN Bio and Mimetas. Emerging players are InSphero, Kirkstall and React4Life. Organovo is listed as an others. Thermo Fisher Scientific is listed as a broad incumbent.
Does SynVivo have an API?
No public API is recorded for SynVivo.
What industry is SynVivo in?
SynVivo's product category is Organ-on-Chip Technology Platforms. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 3826.